Search results
Results From The WOW.Com Content Network
The Lachman test is a clinical test used to diagnose injury of the anterior cruciate ligament (ACL). It is recognized as reliable, sensitive, and usually superior to the anterior drawer test . [ 1 ]
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
The Lachman test is more sensitive than the anterior drawer test. For the Lachman test, the person lies down in supine position with the knee flexed at 20 degrees and the heel touching the bed. The tibia is then pulled forward. If there is 6 to 8 millimeters of laxity, with no definitive resistance when the knee is pulled, then the test is ...
Dementia is a devastating disease that impacts one in 10 older Americans. But while many people want to avoid developing dementia, the exact causes of the condition have remained largely a mystery ...
Vascular dementia, the second most common type of dementia after Alzheimer’s disease, can be caused by atherosclerosis, a buildup of plaque in the arteries that can lead to heart attacks, stroke ...
If the tibia pulls forward or backward more than normal, the test is considered positive. Excessive displacement of the tibia anteriorly suggests that the anterior cruciate ligament is injured, whereas excessive posterior displacement of the tibia may indicate injury of the posterior cruciate ligament. [3]
Probably the best-known dementia screening test of this kind is the mini–mental state examination. A disadvantage of such tests is that they are affected by the person's level of education, familiarity with the dominant language and culture in their country, and level of intelligence before the onset of dementia. [1]
If the blood test is administered to a broader population where the prevalence of dementia is low, a good test will have a lot of false positives, making it a bad test. New anti-amyloid drugs have ...